KLK1 prevents colorectal inflammation-cancer transformation via B1R-mediated ECM pathway

This study comprehensively describes the etiology, diagnosis and treatment of ulcerative colitis (UC). First, the history, characteristics and increasing incidence of UC worldwide are introduced. The diagnostic criteria of UC are summarized, emphasizing the importance of comprehensive clinical symptoms, endoscopy, histopathology and other methods. In terms of treatment, corresponding treatment strategies for UC patients of different severity in clinical practice are described. In addition, the development of new treatment methods, such as cytokine therapy and intestinal microbiota transplantation, are also discussed. The role of the kallikrein-kinin system (KKS) in UC and its potential therapeutic significance are further analyzed. The possibility of KKL1 in the treatment of UC is explored. KLK1 is a tissue kallikrein that is currently being studied as a drug for the treatment of acute cerebral infarction. KLK1 may have the potential to treat UC by relaxing blood vessels and improving microcirculation. Experiments have found that the expression of intestinal tissue kallikrein is reduced in the acute enteritis model, while KLK1 can play a therapeutic role in this model and lead to the restoration of endogenous intestinal tissue kallikrein expression. KLK1 has potential application prospects as a drug for the treatment of acute enteritis, but it also has limitations in clinical applications and requires further in-depth research and improvement. Overall design: RNA-seq profiling of wildtype NCM460 cells and their knockdown cells (siKLK1)